CI Global Healthcare Leaders ETF (CHCL.B.TO)
Price Chart
Key Stats
Customize
| Expense Ratio | Discount or Premium to NAV | Total Assets Under Management | 30-Day Average Daily Volume |
|---|---|---|---|
| 0.38% | -- | 14.24M | -- |
| Dividend Yield | Turnover Ratio | 1 Year Fund Level Flows | Max Drawdown (All) |
| -- | 1.58% | -36.63M | Upgrade |
Basic Info
| Investment Strategy | |
| CHCL seeks to replicate, to the extent reasonably possible, the performance of a global healthcare index, net of expenses. Currently, CHCL seeks to replicate the performance of the Solactive Developed Markets Healthcare 150 CAD Index (CA NTR) (the “Index”). The Index intends to track the performance of the largest 150 companies from the global healthcare industry |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | CI Investments Inc |
| Prospectus Benchmark Index | |
| Solactive DM Healthcare 150 NR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 1.47 yrs |
Net Fund Flows Versus Category
1 Month
% Rank:
--
--
Category Low
--
Category High
1 Year
% Rank:
87
-36.63M
-112.96M
Category Low
467.85M
Category High
3 Months
% Rank:
--
--
Category Low
--
Category High
3 Years
% Rank:
--
--
Category Low
--
Category High
6 Months
% Rank:
--
--
Category Low
--
Category High
5 Years
% Rank:
--
--
Category Low
--
Category High
YTD
% Rank:
--
--
Category Low
--
Category High
10 Years
% Rank:
--
--
Category Low
--
Category High
As of January 31, 2023
Performance Versus Category
As of February 03, 2023. Returns for periods of 1 year and above are annualized.
Annual Total Returns Versus Peers
As of February 05, 2023.
Asset Allocation
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| UnitedHealth Group Inc | 6.61% | 472.02 | 0.25% |
| Johnson & Johnson | 6.20% | 164.61 | -0.56% |
| Eli Lilly and Co | 4.13% | 339.08 | 2.53% |
| Pfizer Inc | 3.84% | 44.06 | -0.63% |
| AbbVie Inc | 3.82% | 145.20 | 0.25% |
| Merck & Co Inc | 3.74% | 102.94 | -0.50% |
|
Roche Holding AG
|
2.95% | -- | -- |
|
Novo Nordisk A/S Class B
|
2.91% | -- | -- |
| Thermo Fisher Scientific Inc | 2.88% | 587.76 | 0.12% |
|
Novartis AG
|
2.73% | -- | -- |
News
Headline
Wire
Time (ET)
Basic Info
| Investment Strategy | |
| CHCL seeks to replicate, to the extent reasonably possible, the performance of a global healthcare index, net of expenses. Currently, CHCL seeks to replicate the performance of the Solactive Developed Markets Healthcare 150 CAD Index (CA NTR) (the “Index”). The Index intends to track the performance of the largest 150 companies from the global healthcare industry |
| General | |
| Security Type | Exchange-Traded Fund |
| Equity Style | Large Cap/Blend |
| Fixed Income Style | -- |
| Broad Asset Class | -- |
| Broad Category | Equity |
| Category Name | Sector Equity |
| Category Index | Morningstar Gbl GR CAD |
| Global Category Name | Healthcare Sector Equity |
| YCharts Categorization | Healthcare Equity |
| YCharts Benchmark | S&P 1500 Health Care (Sector) Total Return (^SP15HCSTR) |
| Prospectus Objective | -- |
| Fund Owner Firm Name | CI Investments Inc |
| Prospectus Benchmark Index | |
| Solactive DM Healthcare 150 NR CAD | 100.0% |
| Broad Asset Class Benchmark Index | |
| ^SPTSX60TR | 100.0% |
| Manager Tenure | |
| Not Disclosed | 1.47 yrs |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM | -- |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | Upgrade |
| Stock | |
| Weighted Average PE Ratio | 22.18 |
| Weighted Average Price to Sales Ratio | Upgrade |
| Weighted Average Price to Book Ratio | Upgrade |
| Weighted Median ROE | Upgrade |
| Weighted Median ROA | Upgrade |
| Forecasted Dividend Yield | Upgrade |
| Forecasted PE Ratio | Upgrade |
| Forecasted Price to Sales Ratio | Upgrade |
| Forecasted Price to Book Ratio | Upgrade |
As of December 31, 2022
Growth Estimates
Fund Details
| Key Dates | |
| Inception Date | 8/12/2021 |
| Last Annual Report Date | 12/31/2021 |
| Last Prospectus Date | 4/21/2022 |
| Attributes | |
| Index Fund |
|
| Inverse Fund | No |
| Leveraged Fund | No |
| Fund of Funds | No |
| Currency Hedged Fund | No |
| Synthetic Replication Fund | No |
| Has Dividend Investment Plan | No |
| Socially Responsible Fund | No |
News
Headline
Wire
Time (ET)